转自：前瞻产业研究院 行业主要上市公司：爱美客(300896)、昊海生科(688366)、华熙生物(688363)、奥园美谷(000615)、华东 医药(000963)、朗姿股份(002612)、华韩整形(430335)等 本文核心数据：轻医美;市场占比;消费情况;热门产品项目;消费意愿;消费人群 1、我国轻医美在整个医美市场占比过半 轻医美是指介于手术整形和生活美容之间的专业医疗美容项目，通过无创或微创等非手术医学手段实现 皮肤管理、轮廓修饰和抗衰年轻化等效果。常见的轻医美项目主要包括注射类、光电类等。重医美通常 指外科手术类医美服务，本质是整形外科手术，旨在通过手术改善身体任何部位的外形，以满足医疗消 费者的多元化美容需求。常见的重医美项目有五官整形、胸部整形、身体轮廓塑造等。 在我国医美市场中，轻医美发展迅速，2024年，轻医美贡献整体医美市场超过一半的市场规模，已经超 过重医美市场，成为医美中主流的美容方式。其中光电类、注射类是主要的项目构成。轻医美凭借其创 伤小、恢复快、效果显著且风险相对较低等优势，完美契合了现代消费者对美的追求以及对生活品质不 被打扰的双重需求。它无需经历大型手术的复杂流程和漫长 ...

上游医美材料商与下游医美机构就童颜针的"破价"正在大打"口水仗"。 起因正是新氧自营诊所复配的童颜针"艾维岚"产品（又称"奇迹童颜"）售价仅为5999元，为市场公价的1/3，这引发了艾维岚品牌方长春圣博玛生 物材料有限公司（下称"圣博玛"）的不满。 圣博玛发文指出，不对新氧诊所销售的艾维岚提供正品保证责任；新氧则强调旗下产品均为正品，指责圣博玛的说法是"无端抹黑"。 童颜针价格战一触即发。 6月19日，新氧CEO金星发文透露将要上市的部分国产童颜针定价更为合理。 新氧确实"不打无准备之仗"。 信风注意到，新氧早在2023年就与上游医美材料商东方妍美（成都）生物技术股份有限公司（下称"东方妍美"）达成战略合作，后者将尚未上市 的童颜针XH301等多款产品的国内商业化权利独家授权给新氧。 随着此番东方妍美踏上港股IPO之路，其XH301的上市进展情况得以披露。 作为东方妍美的核心产品，XH301预计今年下半年完成国内上市审评，欧盟上市注册进程则处于提交阶段。 由于尚未商业化，东方妍美2024年收入仅为0.13亿元，同期亏损仍达到0.64亿元。 核心产品尚未上市便遭遇价格战，东方妍美未来的业绩增长空间正面临考验。 ...

Investment Rating - The report maintains a "Buy" rating for the company [5]. Core Views - The company reported a revenue of 663 million yuan in Q1 2025, a decrease of 17.90% year-on-year, and a net profit of 444 million yuan, down 15.87% [1]. - Despite the challenging industry environment, the company is expected to show performance resilience through internal enhancements and external expansions, including the acquisition of Korean Regen and the development of its product pipeline [2]. - The company’s gross margin remains high at 93.85%, although the net profit margin has temporarily declined due to reduced revenue [3]. Financial Summary - Revenue projections for 2025-2027 are estimated at 3.338 billion yuan, 3.825 billion yuan, and 4.363 billion yuan, respectively, with corresponding net profits of 2.159 billion yuan, 2.464 billion yuan, and 2.793 billion yuan [4]. - The company’s expense ratio increased to 21.93% in Q1 2025, with sales expenses at 654 million yuan and management expenses at 313.6 million yuan [2]. - The company’s cash flow from operations decreased by 37.99% to 333 million yuan in Q1 2025, attributed to declining net profit and changes in working capital [3].

Core Insights - The company reported a stable growth trend in Q1 2025, with revenue of 10.736 billion yuan, a year-on-year increase of 3.12%, and a net profit of 915 million yuan, up 6.06% [1] - The pharmaceutical industrial sector continues to be a key growth driver, with core subsidiary China East Pharmaceutical achieving revenue of 3.621 billion yuan, a 6.52% increase, and a net profit of 843 million yuan, up 12.20% [2] - The company is focusing on innovation, with over 80 projects in its pipeline, and has significantly increased R&D investment by 49.60% to 880 million yuan in Q1 2025 [4] Business Segments - The innovative drug sales in the pharmaceutical industrial sector are gaining momentum, particularly with the expansion of reimbursement indications for the Bai Ling series products [2] - The CAR-T product, Zewokaiolun, has shown strong sales performance, with over 200 certified medical institutions and 154 effective orders placed by the partner company [3] - The company’s self-developed GLP-1 receptor agonist, HDM1002, has entered the final stages of clinical trials, indicating a robust pipeline in the endocrine field [5][6] Medical Aesthetics - The medical aesthetics segment is showing resilience, with the subsidiary Sinclair achieving approximately 238 million yuan in revenue, a 24.37% increase from the previous quarter [9] - The company has a portfolio of 40 high-end medical aesthetic products, with 26 already launched globally, indicating a strong market presence [9] - New products in the medical aesthetics field, including injectable products, are expected to drive further growth in 2025 [10] Future Outlook - The company aims to leverage its innovative capabilities and product differentiation to expand its market share in the medical aesthetics sector, which is projected to grow steadily [12] - The pharmaceutical industrial sector is expected to maintain a strong growth trajectory, supported by ongoing market expansion and product pipeline development [12] - The overall performance in Q1 2025 reflects the company's commitment to innovation and growth, positioning it for future success in the pharmaceutical and medical aesthetics industries [12]